Golasept Tosse Grassa

Golasept Tosse Grassa is an inhalation product that contains the mucolytic agent Ambroxol Hydrochloride. It is marketed in the European Union and is formulated for respiratory administration to help loosen and clear mucus. The preparation is intended for use in patients with productive coughs associated with infections, bronchitis, or chronic obstructive pulmonary disease. It is classified under ATC code R05CB01 as an expectorant/mucolytic for therapeutic use.

Golasept Tosse Grassa is indicated for conditions where mucus clearance is impaired.

- Acute cough associated with respiratory tract infections. - Acute or chronic bronchitis with productive cough. - Chronic obstructive pulmonary disease (COPD) presenting with sputum production. - Post‑viral cough where mucus is thickened. - Adjunct therapy after chest physiotherapy to enhance expectoration.

The safety profile of inhaled Ambroxol Hydrochloride reflects its mucolytic action and typical inhalation tolerability.

Common: - Mild throat irritation or dryness. - Transient cough increase after inhalation. - Unpleasant taste in the mouth. - Slight headache.

Serious: - Allergic skin rash or urticaria. - Severe bronchospasm or wheezing. - Persistent nausea or vomiting. - Swelling of the face, lips, or tongue.

Precautions should be observed before using Golasept Tosse Grassa to minimize risk and ensure appropriate use.

- Assess for known hypersensitivity to Ambroxol or any excipients. - Use cautiously in patients with asthma or a history of bronchospasm. - Evaluate renal or hepatic impairment before initiating therapy. - Avoid use in uncontrolled respiratory infections without medical supervision. - Pregnant or breastfeeding individuals should consult a healthcare professional. - Do not exceed the recommended frequency of inhalations.

Ambroxol Hydrochloride may interact with other medications or substances, influencing its efficacy or safety.

Avoid: - Concurrent use of other mucolytic agents without medical advice. - Combination with strong bronchodilators that may cause excessive airway irritation. - Co‑administration with anticholinergic cough suppressants that could reduce mucus clearance.

Use with caution: - Concurrent inhaled corticosteroids; monitor for local irritation. - Systemic antibiotics for respiratory infections; observe for additive gastrointestinal effects. - Herbal preparations containing expectorants; adjust dosing as needed.